Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rapt Therapeutics Inc (NQ: RAPT )

16.50 -1.71 (-9.39%)
Streaming Delayed Price Updated: 1:15 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 276,470
Open 18.38
Bid (Size) 16.47 (4)
Ask (Size) 16.52 (1)
Prev. Close 18.21
Today's Range 16.35 - 18.44
52wk Range 9.855 - 32.45
Shares Outstanding 34,287,129
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
From RAPT Therapeutics, Inc.
Via Globe NewsWire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace

Performance

YTD
-11.34%
-11.34%
1 Month
-43.08%
-43.08%
3 Month
-7.92%
-7.92%
6 Month
-33.79%
-33.79%
1 Year
-27.57%
-27.57%

More News

Read More
The Latest Analyst Ratings for RAPT Therapeutics
Via Benzinga
S&P 500 Rises 1%; Crude Oil Down Over 4%
Via Benzinga
What 5 Analyst Ratings Have To Say About RAPT Therapeutics
Via Benzinga
4 Analysts Have This to Say About RAPT Therapeutics
Via Benzinga
Dow Extends Rebound, Surges 456 Points
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Nasdaq Jumps Over 200 Points; GitLab Shares Plummet
Via Benzinga
Dow Surges Over 300 Points; US Inflation Rate Drops To 6%
Via Benzinga
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
From RAPT Therapeutics, Inc.
Via Globe NewsWire
RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From RAPT Therapeutics, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
Via Benzinga
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via Globe NewsWire
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer
From RAPT Therapeutics, Inc.
Via Globe NewsWire
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
From RAPT Therapeutics, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Delta Apparel, Farfetch, American Software And Some Other Big Stocks Moving Lower On Friday
Via Benzinga
Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
From RAPT Therapeutics, Inc.
Via Globe NewsWire
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
From RAPT Therapeutics, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.